---
title: Real-world data on tezepelumab in patients with severe asthma in Germany
date: '2024-06-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38866104/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240613182215&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: In this real-life cohort, including a large proportion of
  patients with history of previous biologic use and encompassing various subgroups,
  the majority responded to tezepelumab. Our data further suggest a steroid-sparing
  effect of ...'
disable_comments: true
---
CONCLUSION: In this real-life cohort, including a large proportion of patients with history of previous biologic use and encompassing various subgroups, the majority responded to tezepelumab. Our data further suggest a steroid-sparing effect of ...